Literature DB >> 16825271

Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients.

R Pokan1, P Hofmann, S P von Duvillard, G Smekal, M Wonisch, K Lettner, P Schmid, M Shechter, B Silver, N Bachl.   

Abstract

BACKGROUND: Previous studies have demonstrated that in patients with coronary artery disease (CAD) upward deflection of the heart rate (HR) performance curve can be observed and that this upward deflection and the degree of the deflection are correlated with a diminished stress dependent left ventricular function. Magnesium supplementation improves endothelial function, exercise tolerance, and exercise induced chest pain in patients with CAD.
PURPOSE: We studied the effects of oral magnesium therapy on exercise dependent HR as related to exercise tolerance and resting myocardial function in patients with CAD.
METHODS: In a double blind controlled trial, 53 male patients with stable CAD were randomised to either oral magnesium 15 mmol twice daily (n = 28, age 61+/-9 years, height 171+/-7 cm, body weight 79+/-10 kg, previous myocardial infarction, n = 7) or placebo (n = 25, age 58+/-10 years, height 172+/-6 cm, body weight 79+/-10 kg, previous myocardial infarction, n = 6) for 6 months. Maximal oxygen uptake (VO2max), the degree and direction of the deflection of the HR performance curve described as factor k<0 (upward deflection), and the left ventricular ejection fraction (LVEF) were the outcomes measured.
RESULTS: Magnesium therapy for 6 months significantly increased intracellular magnesium levels (32.7+/-2.5 v 35.6+/-2.1 mEq/l, p<0.001) compared to placebo (33.1+/-3.1.9 v 33.8+/-2.0 mEq/l, NS), VO2max (28.3+/-6.2 v 30.6+/-7.1 ml/kg/min, p<0.001; 29.3+/-5.4 v 29.6+/-5.2 ml/kg/min, NS), factor k (-0.298+/-0.242 v -0.208+/-0.260, p<0.05; -0.269+/-0.336 v -0.272+/-0.335, NS), and LVEF (58+/-11 v 67+/-10%, p<0.001; 55+/-11 v 54+/-12%, NS).
CONCLUSION: The present study supports the intake of oral magnesium and its favourable effects on exercise tolerance and left ventricular function during rest and exercise in stable CAD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825271      PMCID: PMC2564392          DOI: 10.1136/bjsm.2006.027250

Source DB:  PubMed          Journal:  Br J Sports Med        ISSN: 0306-3674            Impact factor:   13.800


  22 in total

Review 1.  The rationale of magnesium supplementation in acute myocardial infarction. A review of the literature.

Authors:  M Shechter; E Kaplinsky; B Rabinowitz
Journal:  Arch Intern Med       Date:  1992-11

2.  Effect of magnesium sulfate on cardiovascular hemodynamics.

Authors:  W J Mroczek; W R Lee; M E Davidov
Journal:  Angiology       Date:  1977-10       Impact factor: 3.619

Review 3.  Magnesium: nature's physiologic calcium blocker.

Authors:  L T Iseri; J H French
Journal:  Am Heart J       Date:  1984-07       Impact factor: 4.749

4.  Anaerobic threshold and lactate turnpoint.

Authors:  H A Davis; J Bassett; P Hughes; G C Gass
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1983

5.  The transition from aerobic to anaerobic metabolism.

Authors:  J S Skinner; T M McLellan; T H McLellan
Journal:  Res Q Exerc Sport       Date:  1980-03       Impact factor: 2.500

Review 6.  Cholesterol lowering and endothelial function.

Authors:  R A Vogel
Journal:  Am J Med       Date:  1999-11       Impact factor: 4.965

7.  Oral magnesium therapy improves endothelial function in patients with coronary artery disease.

Authors:  M Shechter; M Sharir; M J Labrador; J Forrester; B Silver; C N Bairey Merz
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

8.  Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease.

Authors:  Michael Shechter; C Noel Bairey Merz; Hermann Georg Stuehlinger; Joerg Slany; Otmar Pachinger; Babeth Rabinowitz
Journal:  Am J Cardiol       Date:  2003-03-01       Impact factor: 2.778

9.  Hemodynamic effects of intravenously administered magnesium on patients with ischemic heart disease.

Authors:  H S Rasmussen; O G Larsen; K Meier; J Larsen
Journal:  Clin Cardiol       Date:  1988-12       Impact factor: 2.882

Review 10.  Magnesium and blood pressure: review of the epidemiologic and clinical trial experience.

Authors:  P K Whelton; M J Klag
Journal:  Am J Cardiol       Date:  1989-04-18       Impact factor: 2.778

View more
  11 in total

1.  Plasma and dietary magnesium and risk of sudden cardiac death in women.

Authors:  Stephanie E Chiuve; Ethan C Korngold; James L Januzzi; Mary Lou Gantzer; Christine M Albert
Journal:  Am J Clin Nutr       Date:  2010-11-24       Impact factor: 7.045

2.  Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).

Authors:  Muthiah Vaduganathan; Stephen J Greene; Andrew P Ambrosy; Robert J Mentz; Gregg C Fonarow; Faiez Zannad; Aldo P Maggioni; Marvin A Konstam; Haris P Subacius; Savina Nodari; Javed Butler; Mihai Gheorghiade
Journal:  Am J Cardiol       Date:  2013-10-04       Impact factor: 2.778

3.  The effect of acute vs chronic magnesium supplementation on exercise and recovery on resistance exercise, blood pressure and total peripheral resistance on normotensive adults.

Authors:  Lindsy S Kass; Filipe Poeira
Journal:  J Int Soc Sports Nutr       Date:  2015-04-24       Impact factor: 5.150

4.  Decreased magnesium status may mediate the increased cardiovascular risk associated with calcium supplementation.

Authors:  James J DiNicolantonio; Mark F McCarty; James H O'Keefe
Journal:  Open Heart       Date:  2017-05-22

Review 5.  Magnesium and Human Health: Perspectives and Research Directions.

Authors:  Abdullah M Al Alawi; Sandawana William Majoni; Henrik Falhammar
Journal:  Int J Endocrinol       Date:  2018-04-16       Impact factor: 3.257

6.  Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial.

Authors:  Iain Bressendorff; Ditte Hansen; Morten Schou; Burton Silver; Andreas Pasch; Pierre Bouchelouche; Lise Pedersen; Lars Melholt Rasmussen; Lisbet Brandi
Journal:  Kidney Int Rep       Date:  2016-12-30

7.  Dietary and plasma magnesium and risk of coronary heart disease among women.

Authors:  Stephanie E Chiuve; Qi Sun; Gary C Curhan; Eric N Taylor; Donna Spiegelman; Walter C Willett; Joann E Manson; Kathryn M Rexrode; Christine M Albert
Journal:  J Am Heart Assoc       Date:  2013-03-18       Impact factor: 5.501

8.  Magnesium and Space Flight.

Authors:  Scott M Smith; Sara R Zwart
Journal:  Nutrients       Date:  2015-12-08       Impact factor: 5.717

Review 9.  Challenges in the Diagnosis of Magnesium Status.

Authors:  Jayme L Workinger; Robert P Doyle; Jonathan Bortz
Journal:  Nutrients       Date:  2018-09-01       Impact factor: 5.717

10.  Mg-supplementation attenuated lipogenic and oxidative/nitrosative gene expression caused by Combination Antiretroviral Therapy (cART) in HIV-1-transgenic rats.

Authors:  Lama ElZohary; William B Weglicki; Joanna J Chmielinska; Jay H Kramer; I Tong Mak
Journal:  PLoS One       Date:  2019-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.